Go Pro
→ Three companies about to leapfrog Nvidia [And transform the entire industry] (From Eagle Publishing) (Ad)tc pixel Free ETHZ Stock Alerts

Flag Ship Acquisition (ETHZ) Competitors

Flag Ship Acquisition logo
$6.02 +0.45 (+8.08%)
As of 07/2/2026
Compare

ETHZ vs. PBYI, HELP, CMPX, ELYM, and TENX

Should you buy Flag Ship Acquisition stock or one of its competitors? MarketBeat compares Flag Ship Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Flag Ship Acquisition include Puma Biotechnology (PBYI), Cybin (HELP), Compass Therapeutics (CMPX), Eliem Therapeutics (ELYM), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry.

How does Flag Ship Acquisition compare to Puma Biotechnology?

Flag Ship Acquisition (NASDAQ:ETHZ) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Puma Biotechnology has a net margin of 10.69% compared to Flag Ship Acquisition's net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat Flag Ship Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Flag Ship AcquisitionN/A -185.71% -83.12%
Puma Biotechnology 10.69%20.30%12.05%

4.1% of Flag Ship Acquisition shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 15.1% of Flag Ship Acquisition shares are owned by insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Flag Ship Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Puma Biotechnology
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Flag Ship Acquisition's average media sentiment score of 0.00 equaled Puma Biotechnology'saverage media sentiment score.

Company Overall Sentiment
Flag Ship Acquisition Neutral
Puma Biotechnology Neutral

Flag Ship Acquisition has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

Puma Biotechnology has higher revenue and earnings than Flag Ship Acquisition. Flag Ship Acquisition is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flag Ship Acquisition$4.11M27.85-$6.17M-$159.65N/A
Puma Biotechnology$228.40M1.83$31.11M$0.4817.13

Summary

Puma Biotechnology beats Flag Ship Acquisition on 11 of the 12 factors compared between the two stocks.

How does Flag Ship Acquisition compare to Cybin?

Cybin (NASDAQ:HELP) and Flag Ship Acquisition (NASDAQ:ETHZ) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Cybin's return on equity of -68.27% beat Flag Ship Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
CybinN/A -68.27% -58.26%
Flag Ship Acquisition N/A -185.71%-83.12%

In the previous week, Cybin's average media sentiment score of 0.13 beat Flag Ship Acquisition's score of 0.00 indicating that Cybin is being referred to more favorably in the media.

Company Overall Sentiment
Cybin Neutral
Flag Ship Acquisition Neutral

Flag Ship Acquisition has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CybinN/AN/A-$148M-$4.23N/A
Flag Ship Acquisition$4.11M27.85-$6.17M-$159.65N/A

Cybin has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Flag Ship Acquisition has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

17.9% of Cybin shares are held by institutional investors. Comparatively, 4.1% of Flag Ship Acquisition shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Comparatively, 15.1% of Flag Ship Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cybin presently has a consensus target price of $58.75, suggesting a potential upside of 897.45%. Given Cybin's stronger consensus rating and higher probable upside, research analysts clearly believe Cybin is more favorable than Flag Ship Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cybin
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Flag Ship Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Cybin beats Flag Ship Acquisition on 8 of the 12 factors compared between the two stocks.

How does Flag Ship Acquisition compare to Compass Therapeutics?

Flag Ship Acquisition (NASDAQ:ETHZ) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Compass Therapeutics' return on equity of -39.75% beat Flag Ship Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Flag Ship AcquisitionN/A -185.71% -83.12%
Compass Therapeutics N/A -39.75%-35.29%

Flag Ship Acquisition has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

In the previous week, Compass Therapeutics had 3 more articles in the media than Flag Ship Acquisition. MarketBeat recorded 3 mentions for Compass Therapeutics and 0 mentions for Flag Ship Acquisition. Compass Therapeutics' average media sentiment score of 0.79 beat Flag Ship Acquisition's score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Flag Ship Acquisition Neutral
Compass Therapeutics Positive

4.1% of Flag Ship Acquisition shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 15.1% of Flag Ship Acquisition shares are owned by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Compass Therapeutics has a consensus price target of $12.25, suggesting a potential upside of 434.93%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than Flag Ship Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Flag Ship Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Compass Therapeutics
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.87

Flag Ship Acquisition has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flag Ship Acquisition$4.11M27.85-$6.17M-$159.65N/A
Compass Therapeutics$850K485.18-$66.49M-$0.41N/A

Summary

Compass Therapeutics beats Flag Ship Acquisition on 12 of the 16 factors compared between the two stocks.

How does Flag Ship Acquisition compare to Eliem Therapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and Flag Ship Acquisition (NASDAQ:ETHZ) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

In the previous week, Eliem Therapeutics' average media sentiment score of 0.00 equaled Flag Ship Acquisition'saverage media sentiment score.

Company Overall Sentiment
Eliem Therapeutics Neutral
Flag Ship Acquisition Neutral

Eliem Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the broader market. Comparatively, Flag Ship Acquisition has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eliem Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Flag Ship Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 4.1% of Flag Ship Acquisition shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by company insiders. Comparatively, 15.1% of Flag Ship Acquisition shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Flag Ship Acquisition has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eliem TherapeuticsN/AN/A-$35.12M-$0.53N/A
Flag Ship Acquisition$4.11M27.85-$6.17M-$159.65N/A

Eliem Therapeutics' return on equity of -47.03% beat Flag Ship Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Eliem TherapeuticsN/A -47.03% -45.97%
Flag Ship Acquisition N/A -185.71%-83.12%

Summary

Flag Ship Acquisition beats Eliem Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Flag Ship Acquisition compare to Tenax Therapeutics?

Tenax Therapeutics (NASDAQ:TENX) and Flag Ship Acquisition (NASDAQ:ETHZ) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Tenax Therapeutics' return on equity of -56.32% beat Flag Ship Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Tenax TherapeuticsN/A -56.32% -53.12%
Flag Ship Acquisition N/A -185.71%-83.12%

In the previous week, Tenax Therapeutics had 5 more articles in the media than Flag Ship Acquisition. MarketBeat recorded 5 mentions for Tenax Therapeutics and 0 mentions for Flag Ship Acquisition. Tenax Therapeutics' average media sentiment score of 0.00 equaled Flag Ship Acquisition'saverage media sentiment score.

Company Overall Sentiment
Tenax Therapeutics Neutral
Flag Ship Acquisition Neutral

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 4.1% of Flag Ship Acquisition shares are owned by institutional investors. 3.7% of Tenax Therapeutics shares are owned by insiders. Comparatively, 15.1% of Flag Ship Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tenax Therapeutics presently has a consensus price target of $38.00, indicating a potential upside of 133.70%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Tenax Therapeutics is more favorable than Flag Ship Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tenax Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Flag Ship Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Tenax Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, Flag Ship Acquisition has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market.

Flag Ship Acquisition has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tenax TherapeuticsN/AN/A-$52.60M-$1.40N/A
Flag Ship Acquisition$4.11M27.85-$6.17M-$159.65N/A

Summary

Tenax Therapeutics beats Flag Ship Acquisition on 8 of the 14 factors compared between the two stocks.

Get Flag Ship Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for ETHZ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ETHZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ETHZ vs. The Competition

Export
MetricFlag Ship Acquisition IndustryManufacturing SectorNASDAQ Exchange
Market Cap$114.45M$3.14B$4.51B$12.59B
Dividend YieldN/A15.26%16.11%6.52%
P/E Ratio-0.0413.5223.9024.81
Price / Sales27.852,789.88158.4089.92
Price / CashN/A25.3136.2649.23
Price / Book0.215.2312.826.50
Net Income-$6.17M-$35.13M$116.30M$336.03M
7 Day Performance7.89%0.96%0.37%2.68%
1 Month Performance18.27%1.43%1.39%5.50%
1 Year PerformanceN/A12.98%10.62%25.01%

Flag Ship Acquisition Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ETHZ
Flag Ship Acquisition
N/A$6.02
+8.1%		N/AN/A$114.45M$4.11MN/A7
PBYI
Puma Biotechnology
0.8239 of 5 stars		$7.99
-1.5%		N/A+132.7%$412.79M$227.18M16.65200
HELP
Cybin
2.3473 of 5 stars		$6.28
-5.0%		$51.75
+724.0%		N/A$409.71MN/AN/A50
CMPX
Compass Therapeutics
3.3336 of 5 stars		$2.18
-0.5%		$12.25
+461.9%		-18.2%$394.39M$850KN/A20
ELYM
Eliem Therapeutics
N/A$13.04
-2.4%		N/A+907.8%$387.97MN/AN/A9

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ETHZ) was last updated on 7/6/2026 by MarketBeat.com Staff.
From Our Partners
Three companies about to leapfrog Nvidia [And transform the entire industry]
The government just committed $200 billion to building computer chips on American soil - one of the largest te...
Eagle Publishing | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Amazon, Google, Meta, and Microsoft just committed $700 billion
Amazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...
True Market Insiders | Sponsoredtc pixel
You must do this before the OpenAI IPO
OpenAI - the company behind ChatGPT - has begun filing confidential paperwork for what could be the largest IP...
InvestorPlace | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
The Warsh Fed and what it could mean for your savings
The Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...
Reagan Gold Group | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel